Catalent (NYSE:CTLT) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the stock.

A number of other equities research analysts also recently issued reports on the company. Barclays increased their price objective on Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research report on Friday, June 28th. Stephens restated an equal weight rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Finally, Royal Bank of Canada restated a sector perform rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Catalent has an average rating of Hold and an average price target of $55.65.

Catalent Trading Down 0.3 %

Shares of CTLT stock opened at $59.59 on Thursday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. Catalent has a 52-week low of $31.80 and a 52-week high of $60.20. The company has a market capitalization of $10.78 billion, a PE ratio of -9.77, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. The business’s fifty day moving average is $56.66 and its 200 day moving average is $56.03.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. On average, equities research analysts anticipate that Catalent will post -0.17 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Catalent news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders have sold 13,482 shares of company stock valued at $779,852 over the last ninety days. 0.31% of the stock is owned by insiders.

Institutional Trading of Catalent

Several large investors have recently bought and sold shares of CTLT. Nomura Holdings Inc. boosted its position in Catalent by 149.4% during the 4th quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after acquiring an additional 6,881,914 shares in the last quarter. Norges Bank purchased a new position in shares of Catalent during the fourth quarter valued at approximately $116,021,000. Capital World Investors lifted its holdings in shares of Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after purchasing an additional 1,098,474 shares during the last quarter. Magnetar Financial LLC purchased a new position in shares of Catalent during the first quarter valued at approximately $56,429,000. Finally, Cadian Capital Management LP lifted its holdings in shares of Catalent by 14.3% during the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after purchasing an additional 759,600 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.